Bloom Pharmacy

Bloom Science is a clinical-stage biopharmaceutical company dedicated to developing a new class of neuroprotective medicines by harnessing the microbiome-gut-brain axis. The company's proprietary Iris platform identifies specific microbes and metabolites that modulate key neurotransmitters and metabolic pathways involved in neurological diseases. Their lead program, BLM-001, is being developed for the treatment of rare, drug-resistant epilepsies such as Dravet syndrome. Additionally, Bloom Science is advancing a pipeline of live biotherapeutic products for neurodegenerative conditions, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis.